RYM stock holds steady as Ryman Healthcare updates investors

Ryman Healthcare (NZRYME0001S4) stock is supported by the companys FY2026 figures, including revenue of NZD 627.3 million and a net loss after tax of NZD 393.0 million. The investors page remains the main source for the groups latest reporting context and ownership details.

FY2026 revenue and loss

The most recent annual numbers show FY2026 revenue at NZD 627.3 million, while net loss after tax reached NZD 393.0 million. That combination matters more than a simple top-line figure, because it shows a business still carrying heavy accounting and operating pressure across the year.

The same reporting set also points to the scale of the balance-sheet strain, with the loss figure far larger than operating revenue alone would suggest. For Ryman Healthcare stock, that keeps the market focused on whether future periods can narrow losses faster than revenue expands.

Revenue still trails loss

Revenue of NZD 627.3 million against a loss of NZD 393.0 million leaves little room for optimism built only on sales growth. The comparison is straightforward: the company still needs a clearer earnings path before the financial profile improves in a durable way.

Ryman Healthcare stock also needs a market anchor, and the current article uses the companys investor context rather than a live quote because the search set does not provide a dated market-price page. That shifts attention to the dated operational numbers already in hand and to the companys own reporting cadence.

Care portfolio and sales mix

Ryman Healthcares business still rests on retirement villages, aged care, and associated sales activity, so the revenue line alone never tells the whole story. What matters for stock watchers is whether occupancy, deferred sales, and operating margins improve enough to reverse the yearly loss trend.

The annual result of NZD 627.3 million in revenue and NZD 393.0 million in net loss after tax shows that the recovery, if it comes, has to be measured in periods rather than days. That is why the latest investor material matters more than narrative alone.

Representative product line

The most representative product line for Ryman Healthcare is its retirement village and care offering, which connects housing, hospitality-style services, and clinical care into one operating model. The business mix helps explain why annual financial results can remain volatile when asset values, sales timing, and care demand move at different speeds.

For investors, that means the reported numbers should be read as part of a longer turnaround process rather than a single-quarter event. In FY2026, the companys revenue and loss figures remain the clearest guideposts.

Stock closes on report data

Ryman Healthcare stock is priced here through its operating results rather than a live quote, with FY2026 revenue at NZD 627.3 million and net loss after tax at NZD 393.0 million. The latest investor context points to a company still working through a large earnings gap, and the numbers are the key reference point as of 23 July 2026.

Company: Ryman Healthcare Limited
ISIN: NZRYME0001S4
Ticker: NZX: RYM
Trading venue: NZX
Sector / Industry: Real Estate / Residential REIT and retirement living
Index membership: N/A